Trial Profile
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2024
Price :
$35
*
At a glance
- Drugs Budesonide (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Acronyms NefIgArd
- Sponsors Calliditas Therapeutics
- 18 Apr 2024 Results presented in the Calliditas Therapeutics Media Release.
- 18 Apr 2024 According to a Calliditas Therapeutics media release, additional data analyses from this trial were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.
- 08 Apr 2024 According to a Calliditas Therapeutics media release, data from this study will be presented at the International Society of Nephrology's World Congress of Nephrology.